Company news

Immunic, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immunic to Participate in Scientific Conferences in October

October 3, 2023

Immunic to Participate in Industry and Investor Conferences in September

September 5, 2023

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

August 16, 2023

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 2, 2023

Immunic to Participate in Investor and Scientific Conferences in August

July 31, 2023

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

July 26, 2023

Immunic to Participate in Scientific and Investor Conferences in July

June 28, 2023

Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases

June 25, 2023

Immunic to Participate in Scientific and Investor Conferences in June

May 29, 2023

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

May 16, 2023

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 10, 2023

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update

May 8, 2023

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

May 5, 2023

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

May 3, 2023

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

April 26, 2023

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

April 4, 2023

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update

February 22, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

February 21, 2023

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update

February 15, 2023

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

February 8, 2023

Immunic to Participate in Scientific and Investor Conferences in February

January 24, 2023

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

November 16, 2022

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 2, 2022

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update

October 26, 2022

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

October 19, 2022

Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing

October 9, 2022

Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

September 19, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

August 15, 2022

Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 3, 2022

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

July 27, 2022

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén

July 5, 2022

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

June 14, 2022

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June

June 7, 2022

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

June 1, 2022

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

May 4, 2022

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update

May 2, 2022

Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer

March 15, 2022

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

February 23, 2022

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Co...

February 17, 2022

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

February 16, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

February 1, 2022

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

December 13, 2021

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

December 8, 2021

Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

November 17, 2021

Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity

November 3, 2021

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate Update

October 31, 2021

Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis

October 27, 2021

Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935

October 26, 2021

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

October 13, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 13 calls. Every call is listed under its year.

Decks

The 5 newest of 68 decks. Every deck is listed under its year.